Laura Mahecha
Director of Agrochemicals, Chemicals & Materials
Recent M&A activity in the biocontrol industry, including biopesticides and biostimulants, has been driven by large crop protection companies and private equity investors seeking growth in biological agriculture. The primary themes have centered on a few key areas:
Expanding biostimulant and biocontrol portfolios
Acquiring novel microbial technologies
Adding fermentation and R&D capabilities
Building scale in a still-fragmented market
Key takeaways
Syngenta’s expansion of its biologicals platform through Intrinsyx Bio and biological research assets from Novartis.
Consolidation in biostimulants, including HGS BioScience’s acquisition of NutriAg and Synsus’ acquisition of Emerald Bioagriculture.
Private equity investment, illustrated by Ardabelle Capital’s agreement to acquire a majority stake in Plymag.
Overall, the sector remains in a consolidation phase, with buyers focusing on microbial technology, biostimulants, nutrient-use-efficiency products, manufacturing capacity, and specialized biological R&D capabilities.
Large crop protection companies continue to expand their biological platforms
Large crop protection companies continue investing in biologicals through acquisitions, partnerships, licensing agreements, and expanded manufacturing capacity. According to Syngenta, the global biologicals market is projected to reach nearly USD 20 billion by 2030.
In February 2025, Syngenta announced the acquisition of Novartis’ repository of natural compounds and genetic strains for agricultural use. The agreement included the transfer of the Natural Products and Biomolecular Chemistry team and access to fermentation and laboratory facilities in Basel, Switzerland. The acquisition expands Syngenta’s access to natural-product research, bioengineering, fermentation, downstream processing, analytics, and novel leads for agricultural biologicals.
Syngenta also acquired California-based Intrinsyx Bio, a company specializing in nutrient-use-efficiency products. The acquisition strengthens Syngenta’s biologicals portfolio and innovation pipeline in nutrient-use efficiency and plant nutrition technologies.
Microbial technologies are attracting buyer interest
Companies that possess these technologies are receiving significant interest because they offer differentiated intellectual property and specialized capabilities. This includes companies with:
Microbial strain collections
Fermentation expertise
Nutrient-use-efficiency technologies
Biocontrol modes of action
A recent example is HGS BioScience’s acquisition of Canadian biostimulant company NutriAg, Ltd. in October 2025. The transaction combined humic and fulvic acid technologies, seaweed extracts, amino acids, carbohydrate-based technologies, and microbial products. It also expanded the combined company’s reach across the United States and Canada. The transaction demonstrates private equity interest in biological agriculture and reflects ongoing consolidation among specialty biostimulant suppliers.
Biostimulants remain highly fragmented
Unlike conventional crop protection, the biostimulants sector still consists of many regional companies. This fragmentation is encouraging acquisitions by strategic buyers and private equity firms seeking scale. Manufacturing capacity has become an important acquisition consideration, and buyers increasingly value:
Fermentation facilities
Microbial production assets
Formulation capabilities
Registration expertise
The Syngenta-Novartis transaction is one example because it combined intellectual property with scientific personnel, fermentation capabilities, and laboratory infrastructure.
Another example is Ardabelle Capital’s December 2025 agreement to acquire a majority stake in Plymag, a Spanish company specializing in biostimulants and crop nutrition. The investment was intended to support international expansion, strengthen R&D, and develop Plymag’s biological crop-input platform.
In March 2026, Synsus Private Label Partners acquired Emerald Bioagriculture, a developer of biostimulant technologies. According to Synsus, the transaction combined Emerald’s product line with Synsus’ R&D, formulation, manufacturing, and private-label capabilities to accelerate the development of bio-based plant-health solutions.
